4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Blood, blood components, plasma, and plasma products

      other
      , BS, PharmD, BCCCP * , , 1 , , PharmD, BCIDP, AAHIVP * , , , PharmD, BCCCP * , § , , PharmD, BCPS * , , , PhD, FACN
      Side Effects of Drugs Annual
      Elsevier B.V.
      Adverse reactions, Albumin, Alpha1-antitrypsin, Anti-D immunoglobulin, Antithrombin III, Blood substitutes, Blood transfusion, C1 esterase inhibitor concentrate, Coagulation proteins, Cryoprecipitate, Epoetin, Erythrocytes, Erythropoietin, Etherified starches, Factor I, Factor II, Factor IX, Factor VIIa, Factor VIII, Fresh frozen plasma, Gelatin, Globulins, Granulocytes, Hemoglobin-based oxygen carriers, Immunoglobulins, Intravenous immunoglobulin, Pharmacogenomics, Plasma products, Plasma substitutes, Platelets, Prothrombin complex concentrate, Side effects, Stem cells, Subcutaneous immunoglobulin, Thrombopoietin and receptor agonists, Von Willebrand factor

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review of 2018 publications identifies side effects of blood, blood components, and plasma products. In addition, albumin, blood transfusion (erythrocytes, granulocytes, and platelets), blood substitutes (hemoglobin-based oxygen carriers), plasma products (alpha1-antitrypsin, C1 esterase inhibitor concentrate, cryoprecipitate, and fresh frozen plasma), plasma substitutes (etherified starches, and gelatin), globulins (intravenous immunoglobulin, subcutaneous immunoglobulin, and anti-D immunoglobulin), coagulation proteins (factor I, factor II, factor VIIa, factor VIII, factor IX, prothrombin complex concentrate, antithrombin III, and von Willebrand factor/factor VIII concentrates), erythropoietin and derivatives, thrombopoietin and receptor agonists, transmission of infectious agents through blood donation, and stem cells are reviewed. This chapter informs the reader about newly recognized and published data in the blood product domain.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Adverse Effects of Immunoglobulin Therapy

          Immunoglobulin has been widely used in a variety of diseases, including primary and secondary immunodeficiency diseases, neuromuscular diseases, and Kawasaki disease. Although a large number of clinical trials have demonstrated that immunoglobulin is effective and well tolerated, various adverse effects have been reported. The majority of these events, such as flushing, headache, malaise, fever, chills, fatigue and lethargy, are transient and mild. However, some rare side effects, including renal impairment, thrombosis, arrhythmia, aseptic meningitis, hemolytic anemia, and transfusion-related acute lung injury (TRALI), are serious. These adverse effects are associated with specific immunoglobulin preparations and individual differences. Performing an early assessment of risk factors, infusing at a slow rate, premedicating, and switching from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) can minimize these adverse effects. Adverse effects are rarely disabling or fatal, treatment mainly involves supportive measures, and the majority of affected patients have a good prognosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

            Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016)

              Background and purpose The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in February 2017 and published in the Journal of JSICM, [2017; Volume 24 (supplement 2)] 10.3918/jsicm.24S0001 and Journal of Japanese Association for Acute Medicine [2017; Volume 28, (supplement 1)] http://onlinelibrary.wiley.com/doi/10.1002/jja2.2017.28.issue-S1/issuetoc. This abridged English edition of the J-SSCG 2016 was produced with permission from the Japanese Association of Acute Medicine and the Japanese Society for Intensive Care Medicine. Methods Members of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine were selected and organized into 19 committee members and 52 working group members. The guidelines were prepared in accordance with the Medical Information Network Distribution Service (Minds) creation procedures. The Academic Guidelines Promotion Team was organized to oversee and provide academic support to the respective activities allocated to each Guideline Creation Team. To improve quality assurance and workflow transparency, a mutual peer review system was established, and discussions within each team were open to the public. Public comments were collected once after the initial formulation of a clinical question (CQ) and twice during the review of the final draft. Recommendations were determined to have been adopted after obtaining support from a two-thirds (> 66.6%) majority vote of each of the 19 committee members. Results A total of 87 CQs were selected among 19 clinical areas, including pediatric topics and several other important areas not covered in the first edition of the Japanese guidelines (J-SSCG 2012). The approval rate obtained through committee voting, in addition to ratings of the strengths of the recommendation, and its supporting evidence were also added to each recommendation statement. We conducted meta-analyses for 29 CQs. Thirty-seven CQs contained recommendations in the form of an expert consensus due to insufficient evidence. No recommendations were provided for five CQs. Conclusions Based on the evidence gathered, we were able to formulate Japanese-specific clinical practice guidelines that are tailored to the Japanese context in a highly transparent manner. These guidelines can easily be used not only by specialists, but also by non-specialists, general clinicians, nurses, pharmacists, clinical engineers, and other healthcare professionals. Electronic supplementary material The online version of this article (10.1186/s40560-017-0270-8) contains supplementary material, which is available to authorized users.
                Bookmark

                Author and article information

                Contributors
                Journal
                Side Effects of Drugs Annual
                Elsevier B.V.
                0378-6080
                0378-6080
                28 August 2019
                2019
                28 August 2019
                : 41
                : 373-386
                Affiliations
                [* ]Department of Pharmacy Practice and Administration, Rutgers, The State University of New Jersey, Piscataway, NJ, United States
                []Medical Intensive Care Unit, Saint Barnabas Medical Center, Livingston, NJ, United States
                []Hunterdon Medical Center, Flemington, NJ, United States
                [§ ]Hackensack University Medical Center, Hackensack, NJ, United States
                []Jersey Shore University Medical Center, Neptune City, NJ, United States
                []Department of Pharmaceutical & Biomedical Sciences, Touro College of Pharmacy & School of Osteopathic Medicine, Manhattan, NY, United States
                Author notes
                Article
                S0378-6080(19)30011-X
                10.1016/bs.seda.2019.07.007
                7148809
                a0e3d0d5-053c-4e50-bb4a-5219582614eb
                Copyright © 2019 Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                adverse reactions,albumin,alpha1-antitrypsin,anti-d immunoglobulin,antithrombin iii,blood substitutes,blood transfusion,c1 esterase inhibitor concentrate,coagulation proteins,cryoprecipitate,epoetin,erythrocytes,erythropoietin,etherified starches,factor i,factor ii,factor ix,factor viia,factor viii,fresh frozen plasma,gelatin,globulins,granulocytes,hemoglobin-based oxygen carriers,immunoglobulins,intravenous immunoglobulin,pharmacogenomics,plasma products,plasma substitutes,platelets,prothrombin complex concentrate,side effects,stem cells,subcutaneous immunoglobulin,thrombopoietin and receptor agonists,von willebrand factor

                Comments

                Comment on this article